PHILADELPHIA, Sept. 19, 2014 (GLOBE NEWSWIRE) -- Michael Goldberg M.D. and Shepard M. Goldberg, both recently elected board members of Echo Therapeutics (Nasdaq:ECTE), will host a conference call with investors to discuss recent developments and also their goals to establish a new strategic direction for the company which will require the removal of the three predecessor directors for cause. In light of recent events at Echo Therapeutics, Dr. Goldberg and Mr. Goldberg have been contacted by a number of shareholders regarding their concerns about the stock price and lack of information from the current management team.
Dr. Michael Goldberg was appointed to Echo's Board of Directors in February 2014 and elected for a three-year term by shareholders at this past years annual meeting. Shepard Goldberg was also elected to the Board of Directors at the 2014 Annual Meeting of Stockholders held on Thursday, June 19, 2014. Shepard Goldberg was nominated by the Platinum Group, a stockholder group led by Platinum Management, the company's largest shareholder in opposition to the Board's nominee in a contested proxy fight. Shepard Goldberg was an overwhelming choice, winning with close to a 4-1 margin.
Dr. Goldberg and Shepard Goldberg will provide a brief overview of the current situation and their plans for Echo Therapeutics. They will then entertain questions and are open to suggestions for changing, what they consider to be, a correctable situation, but only if immediate action is taken to reorient the Company.
|Conference Call & Webcast|
|Monday, September 22nd @ 8:30 AM Eastern Time/5:30 AM Pacific Time|
CONTACT: Michael Goldberg MD (201) 608 5218Source:Michael Goldberg